Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 219 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Bausch Health Americas, Inc. Clear all
Completed Phase 2 Interventional

Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction

NCT01367574
View directory record Official record
Conditions
Bowel Dysfunction
Interventions
SC MNTX
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Phase 3 Interventional

Study of Methylnaltrexone (MNTX) for the Relief of Constipation

NCT00402038
View directory record Official record
Conditions
Advance Illness Patients With OIC
Interventions
SC Methylnaltrexone, SC Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Phase 4 Interventional Results available

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

NCT01842581
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
43
States / cities
Phoenix, Arizona • Coronado, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

A Study of Acne Treatment in Children Ages 9 to 11

NCT00907335
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Retin-A Micro 0.04% facial acne treatment, Vehicle control
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 11 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Encino, California • San Diego, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

NCT00529087
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728), placebo
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Mobile, Alabama • Sun City, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Phase 1 Interventional

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

NCT03058744
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-118 Lotion, HP Monad Lotion, Ultravate Cream, Tazorac Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Anaheim, California • Encino, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

12-Week Study of Plecanatide for CIC (The National CIC3 Study)

NCT02122471
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
167
States / cities
Anniston, Alabama • Huntsville, Alabama • Chandler, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone

NCT01367587
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IV Methylnaltrexone
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Phase 2 Interventional Results available

(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis

NCT02047604
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAN-300 0.5 mg/kg QW, SAN-300 1.0 mg/kg QW, SAN-300 2.0 mg/kg QOW, SAN-300 4.0 mg/kg QOW, SAN-300 4.0 mg/kg QW, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • El Cajon, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function

NCT01367509
View directory record Official record
Conditions
Renal Impairment
Interventions
Methylnaltrexone (MNTX)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 6, 2026, 1:07 PM EDT
Terminated Phase 4 Interventional

A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting

NCT00418678
View directory record Official record
Conditions
Nausea and Vomiting
Interventions
Cesamet
Drug
Lead sponsor
Veeda Oncology
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2010 · Synced Oct 6, 2026, 1:07 PM EDT
Recruiting Phase 4 Interventional

Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

NCT07285785
View directory record Official record
Conditions
Diarrhea, Gastroenteritis, Bacterial Infection, Acute Diarrhea
Interventions
Rifaximin 200 mg Tablet, Oral Rehydration Therapy (ORT)
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Lynwood, California • Hialeah, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 6, 2026, 1:07 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects

NCT01708590
View directory record Official record
Conditions
Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Bakersfield, California • Encino, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Phase 4 Interventional Results available

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

NCT00672477
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
29
States / cities
Mobile, Alabama • Laguna Hills, California • Lancaster, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety Study of Plecanatide

NCT02706483
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Plecanatide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
204
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 200 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists

NCT00443872
View directory record Official record
Conditions
Parkinson's Disease
Interventions
orally disintegrating selegiline (Zelapar)
Drug
Lead sponsor
Parkinson's Disease and Movement Disorder Center of Boca Raton
Other
Eligibility
30 Years to 90 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability

NCT03063489
View directory record Official record
Conditions
Eye Pain
Interventions
Loteprednol Etabonate Ophthalmic Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
6
States / cities
Phoenix, Arizona • Oceanside, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 6, 2026, 1:07 PM EDT
Terminated Phase 3 Interventional Results available

One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

NCT02240108
View directory record Official record
Conditions
Crohn's Disease
Interventions
Rifaximin EIR, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
78
States / cities
Huntsville, Alabama • Tucson, Arizona • Sherwood, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 6, 2026, 1:07 PM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis

NCT02029495
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
210 mg brodalumab, 140 mg brodalumab, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
43
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Phase 4 Interventional Results available

Mesalamine to Reduce T Cell Activation in HIV Infection

NCT01090102
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases, Immune System Diseases, Lentivirus Infections, Acquired Immunodeficiency Syndrome
Interventions
Mesalamine (5-aminosalicylic acid, Apriso), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Not applicable Interventional Results available

A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans

NCT01542541
View directory record Official record
Conditions
Intestinal FDG Uptake
Interventions
Rifaximin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 6, 2026, 1:07 PM EDT
Terminated Phase 2 Interventional

Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C

NCT00305383
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Viramidine, Peginterferon alfa-2b
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Los Angeles, California • San Mateo, California • Bradenton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 6, 2026, 1:07 PM EDT
Completed No phase listed Observational

Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)

NCT00360932
View directory record Official record
Conditions
Facial Lipoatrophy
Interventions
SCULPTRA (poly-L-lactic acid injection)
Device
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 6, 2026, 1:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects

NCT03327558
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Apriso 0.375G ER CAP, APRISO 375 mg extended-release capsules
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 6, 2026, 1:07 PM EDT